

DTN: participating in studies? This is what's going on!

Amica Ko

Erasmus MC

PhD Representative DTN Board

Disclosure belangen spreker – Amica Ko	
Nederlands Trombose Congres – 16 mei 2025	
(potentiële) Belangenverstrengeling	
Voor bijeenkomst mogelijk relevante relaties met bedrijven	Geen
<ul style="list-style-type: none"> • Sponsoring of onderzoeksgeld • Honorarium of andere (financiële) vergoeding • Aandeelhouder • Andere relatie, namelijk: 	Geen

Dutch Thrombosis Network (DTN)

- Independent, non-profit collaboration initiative of academic and non-academic venous thrombosis researchers in the Netherlands
- Affiliated with INVENT-VTE (International Network of Venous Thromboembolism Clinical Research Networks)

➔ To encourage nationwide collaboration in clinical studies



Dutch Thrombosis Network
*Netwerk van klinische en
niet-klinische tromboseonderzoekers*

Studies currently supported by DTN

- PEITHO
- SERENITY
- L-TRIPP
- PE@HOME

Studies currently supported by DTN

- PEITHO
- SERENITY
- **L-TRIPP**
- **PE@HOME**

Leiden Thrombosis Recurrence Risk Prediction (L-TRiPP) Study

Long-term anticoagulation use after first VTE:

Preventing recurrences but increased risk of (major) bleeding!

Models to predict risk of recurrence (L-TRiPP) and bleeding (VTE-BLEED): duration of treatment short-term versus ongoing?


➔ To optimize treatment duration of anticoagulation after a first VTE based on the classification of the risk of recurrence and major bleeding

Design

Cohort-based RCT

Primary outcomes:
Recurrence or major bleeding

Secondary outcomes:
Quality of life, disability, cost-effectiveness



Updates

- Start inclusions: June 2021
- Sample size: +/- 1150 patients
→ 986 included, expected to reach sample size this year
- Not open for new centers (now: 20) to participate

More information?

✉ L-TRRiP@lumc.nl (Ruben Kok)





PE@HOME study

Post-pulmonary embolism (PE) syndrome =

Persistent functional limitations after diagnosis of an acute PE

➔ Up to 50% of acute PE survivors report persistent symptoms after 3 months!*

Early exercise training programs with possible benefit!

Objectives



Primary

- To determine the effect of a 8-week standardized exercise training program in PE patients **<4 weeks** after diagnosis **with persistent dyspnea and functional limitations**, on physical performance


Secondary

- To assess the incidence of PPES and quality of life
- To investigate the difference in cardiopulmonary functioning
- To evaluate safety and cost-effectiveness of the intervention

Design



Time scale
From PE event





Updates

- First inclusions: February 2022
- Target sample size: 90
→ $79/90 = 88\%$ included!
- Not open for new centers to participate (check whether your hospital still need to include patients... 😊)

More information?

✉ r.m.a.mali@lumc.nl (Rosa)

Other ongoing clinical studies in NL

- TORPEDO-NL
- DISTINCT
- Hydra


Other ongoing clinical studies in NL

- **TORPEDO-NL**
- DISTINCT
- Hydra

Thrombectomy in high-risk pulmonary embolism – device versus thrombolysis (TORPEDO-NL)

Treatment of high-risk PE patients

- Systemic thrombolysis (“standard”)
 - 10-25% risk of **major bleeding**
 - 3% **intracranial bleeding**
- Thrombectomy = catheter assisted thrombosuction
 - Directer effect on **reducing clot formation** in pulmonary artery
 - Most likely a **better safety profile**
 - **Limited availability of RCTs** on safety and efficacy




Objectives

- To determine whether thrombectomy is more effective and safer compared to systemic thrombolysis and whether it leads to a better Desirability of Outcome Ranking (DOOR)
- To investigate if thrombectomy is associated with
 - Lower levels of oxygen suppletion
 - Shorter ICU or hospital admission duration
 - Better functional recovery or quality of life
- To evaluate if thrombectomy is more cost-effective than systemic thrombolysis

Design

- Investigator-initiated, academically sponsored, multicenter, open-label, RCT
- Thrombectomy versus systemic thrombolysis (2:1)
- 111 high-risk PE patients

Figure 1: Study flowchart.



Note: PE: pulmonary embolism, CDT: Catheter-directed thrombectomy, ICU: intensive care unit

Updates



December 2024
METC approval



Rijnstate

Centers started



Included patients



6/15

2/111

Recruitment

Interested in participating? Study is still open!



www.torpedo-nl.nl



w.j.e.stenger@lumc.nl (Justine)

Justine Stenger - LUMC

Corstiaan den Uil - Maasstad Ziekenhuis

Wim Rietdijk - VU/Erasmus UMC

Adriaan Kraaijeveld - UMCU

Erik Klok - LUMC

Other ongoing clinical studies in NL

- TORPEDO-NL
- **DISTINCT**
- Hydra



DISTINCT trial

“inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hip or total knee replacement”

- Patients undergoing major orthopaedic surgery at high risk of developing VTE despite the use of prophylactic anticoagulants
- Prophylaxis in “fast-track” mobilization protocols not well studied:
 - Overtreating those with low-risk?
 - Undertreating those with high-risk?




Objectives

- To determine whether in-hospital thrombosis prophylaxis only is as effective compared with the standard thrombosis prophylaxis approach to prevent symptomatic VTE after total knee and hip arthroplasty in patients with a low VTE risk.
- To determine the incidence of symptomatic VTE after total knee and hip arthroplasty in patients with an intermediate VTE risk.
- To determine whether intensified thrombosis prophylaxis is more effective and equally safe compared with standard thrombosis prophylaxis to prevent symptomatic VTE in patients with a high VTE risk by comparing symptomatic VTE and bleeding complications.



Design

- Multi-arm, national, multicenter, randomized, open-label trial
- TRiP(plasty) score
- Follow-up to 3 months after surgery





Updates

- First inclusion: November 2024
- Sample sizes
 - DISTINCT 1: 3,478
 - DISTINCT 2: 2,500
 - DISTINCT 3: 4,100
- 335 inclusions, but still open for additional hospitals (currently 11) to participate!

Interested in participating or more information?

✉ r.y.kok@lumc.nl (Ruben)

Other ongoing clinical studies in NL

- TORPEDO-NL
- DISTINCT
- **Hydra**

Hydra study

YEARS-criteria as diagnostic strategy for patients with suspected pulmonary embolism (PE), but applicability in patients with malignancies?





Figure 1: YEARS algorithm
CTPA=computed tomography pulmonary angiography.

➔ To prospectively validate the safety and efficiency of management according to the YEARS algorithm to safely rule out clinically suspected PE in patients with active malignancy to be compared with “standard” management by CTPA alone


Design

- Multicenter international RCT
- Randomization 1:1
- Follow-up period of 3 months



Updates

- Start inclusions: July 2019
- Sample size: 1566
→ 680 patients included!



Still recruiting new centers/hospitals!

Interested in participating or more information?

✉ b.akerboom@lumc.nl (Bram)

Interested in collaboration?



Dutch Thrombosis Network

*Netwerk van klinische en
niet-klinische tromboseonderzoekers*

<https://www.dutchthrombosisnetwork.org/>

 info@dutchthrombosisnetwork.org